{
    "2019-05-05": [
        [
            {
                "time": "2018-01-01",
                "original_text": "【西南医药】医药行业2018年年报及2019年一季报总结：行业分化明显，疫苗、CRO和药店等表现抢眼",
                "features": {
                    "keywords": [
                        "医药行业",
                        "年报",
                        "一季报",
                        "行业分化",
                        "疫苗",
                        "CRO",
                        "药店"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗",
                        "CRO",
                        "药店"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-29",
                "original_text": "申万宏源一周晨会纪要合集（2019/4/29-2019/4/30）",
                "features": {
                    "keywords": [
                        "申万宏源",
                        "晨会纪要",
                        "周报"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-01-01",
                "original_text": "【招商医药】医药生物行业18年年报及19年一季报回顾---医药整体业绩探底，内部分化明显",
                "features": {
                    "keywords": [
                        "医药生物",
                        "年报",
                        "一季报",
                        "业绩探底",
                        "内部分化"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-01",
                "original_text": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
                "features": {
                    "keywords": [
                        "国盛医药",
                        "年报",
                        "季报",
                        "野蛮扩张",
                        "结构优化",
                        "医药流通"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药流通"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}